New drug cocktail aims to outsmart Treatment-Resistant melanoma
NCT ID NCT06594991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of three drugs—fianlimab, cemiplimab, and ipilimumab—can safely shrink tumors in people with advanced melanoma that no longer responds to standard PD-1 therapy. The study enrolls 88 adults with locally advanced or metastatic melanoma. Researchers will measure how many patients see their tumors shrink and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fianlimab, cemiplimab, and ipilimumab (drug combination)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced melanoma that no longer responds to standard immunotherapy.
- What could go wrong
- This is an early phase 2 trial with only 88 participants, so results may not apply to everyone. The drug combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Hackensack Meridian Health (Data Collection Only)
RECRUITINGHackensack, New Jersey, 07601, United States
-
Hartford Healthcare Alliance (Data Collection Only)
RECRUITINGHartford, Connecticut, 06102, United States
-
MD Anderson Cancer Center (Data Collection Only)
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
-
Stanford University (Data Collection Only)
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?